Helix BioPharma provides update to shareholders; appoints William White as interim CEO on Thursday after the close (HBP) 1.75 : Co announces approved the initiation of Helix's planned Polish Phase I/II clinical trial of its lung cancer drug candidate L-DOS47 according to the approved protocol beginning with the monotherapy arm. The co currently plans to commence patient recruitment in this study before the end of its third fiscal quarter in April 2012, and will report on the expected schedule for this study when it is available. William White, Helix's Chairman of the Board, has been appointed as interim Chief Executive Officer to replace Donald Segal who has resigned as of the date of this announcement, as was previously anticipated. In this capacity, White will oversee the management, operations and financing strategies of the Company in the short term and immediately implement a search for a permanent CEO.
